Trial · NCT07341958
INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)
NCT07341958, Not applicable, Not yet recruiting, Beijing Tiantan Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2). Trials, record NCT07341958. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07341958
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)
- NCT number
- NCT07341958
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 242 participants, estimated
- Lead sponsor
- Beijing Tiantan Hospital
- Conditions
- Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
- Interventions
- Tafolecimab, Placebo
- First posted
- 2026-01-15
- Last updated
- 2026-10-08
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage change in Lp(a) from baseline at 90 days. | From baseline to 90 days after randomization | |
| Secondary | Incidence of new stroke (including hemorrhagic and ischemic stroke) within 90 days. | From baseline to 90 days after randomization | Symptoms and signs of acute neurological deficits caused by sudden focal or whole brain, spinal cord or retinal vascular damage, which are related to cerebral circulatory disorders, including hemorrhagic and ischemic stroke |
| Secondary | Incidence of composite clinical endpoint events within 90 days | From baseline to 90 days after randomization | Including recurrent ischemic stroke, myocardial infarction, rehospitalization for unstable angina or heart failure, and cardiovascular death |
| Secondary | Incidence of myocardial infarction within 90 days. | From baseline to 90 days after randomization | Acute myocardial infarction is diagnosed by the third edition of the international general diagnostic criteria (Glob Heart. 2012 Dec;7(4):275-95) |
| Secondary | Incidence of vascular death within 90 days. | From baseline to 90 days after randomization | Vascular death includes stroke, sudden cardiac death, acute myocardial infarction, heart failure, pulmonary embolism, heart / cerebrovascular intervention or surgery (death unrelated to acute MI) and other cardiovascular causes of death \[such as: Arrhythmia irrelevant with sudden cardiac death, aortic aneurysm rupture, or peripheral artery disease. Any death of unknown/unclear cause that occurs within 30 days after stroke, myocardial infarction, or cardio-cerebrovascular operation/surgery will be regarded as death due to stroke, myocardial infarction, or cardio-cerebrovascular operation/surgery, respectively. |
| Secondary | Incidence of all-cause death within 90 days. | From baseline to 90 days after randomization | |
| Secondary | Proportion of patients with poor functional outcome (mRS score 2-6) at 90 days. | From baseline to 90 days after randomization | The Modified Rankin Scale (mRS) score ranges from 0 to 6, with higher scores indicating worse functional outcome. The modified Rankin Scale (mRS)= 2-6: poor functional outcome |
| Secondary | Proportion of patients with Lp(a) <30 mg/dL at 90 days | From baseline to 90 days after randomization | |
| Secondary | Percent reduction in ApoB and LDL-C levels from baseline to 90 days | From baseline to 90 days after randomization | |
| Secondary | LDL-C goal attainment rate (<1.8 mmol/L or reduction ≥ 50%) at 90 days | From baseline to 90 days after randomization |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07341958
GET https://conductscience.org/api/trials/v1/NCT07341958/registered